The price of HUTCHMED (China) Limited (NASDAQ:HCM) shares last traded on Wall Street fell -17.91% to $13.57.
Based on available information, 14 analysts follow HUTCHMED (China) Limited (NASDAQ:HCM). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $50.00 and a low of $15.00, we find $26.16. Given the previous closing price of $16.53, this indicates a potential upside of 58.26 percent. HCM stock price is now -20.25% away from the 50-day moving average and 5.90% away from the 200-day moving average. The market capitalization of the company currently stands at $2.40B.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Among analysts, 1 rate the stock a hold while 13 rate it a buy. Brokers who have rated the stock have averaged $29.79 as their price target over the next twelve months.
On September 22, 2021, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock keeping its target price maintained at $46, while ‘Jefferies’ rates the stock as ‘Buy’.
A total of 0.41% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HCM stock. A new stake in HUTCHMED (China) Limited shares was purchased by CANNON GLOBAL INVESTMENT MANAGEMENT, LLC during the first quarter worth $8,989,000. HRT FINANCIAL LP invested $4,097,000 in shares of HCM during the first quarter. In the first quarter, ERGOTELES LLC acquired a new stake in HUTCHMED (China) Limited valued at approximately $3,515,000. D. E. SHAW & CO., INC. acquired a new stake in HCM for approximately $3,268,000. QUBE RESEARCH & TECHNOLOGIES LTD purchased a new stake in HCM valued at around $1,147,000 in the second quarter. In total, there are 177 active investors with 24.00% ownership of the company’s stock.
A candlestick chart of HUTCHMED (China) Limited (NASDAQ: HCM) showed a price of $15.73 on Wednesday morning. During the past 12 months, HUTCHMED (China) Limited has had a low of $7.39 and a high of $21.44. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 2.40, and a quick ratio of 2.20. The fifty day moving average price for HCM is $17.02 and a two-hundred day moving average price translates $12.81 for the stock.
The latest earnings results from HUTCHMED (China) Limited (NASDAQ: HCM) was released for Jun, 2022. The net profit margin was -84.60% and return on equity was -42.70% for HCM.
HUTCHMED (China) Limited(HCM) Company Profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3′-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton’s tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Leave a Reply